• Vaccine Name: L. amazonensis M2 protein vaccine
• Target Pathogen: Leishmania amazonensis
• Target Disease: Leishmaniasis
• Vaccine Ontology ID: VO_0011355
• Type: Subunit vaccine
• Status: Research
• Host Species as Laboratory Animal Model: mouse
• Antigen: L. amazonensis M2
• M2 gene engineering:
  • Type: Recombinant protein preparation
  • Description: M-2, a 46-kDa promastigote-specific glycoprotein was isolated. The protein was further purified by removal of detergent with an anionexchange column(Champsi and McMahon-Pratt, 1988).
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0001259
• Immunization Route: Intraperitoneal injection (i.p.)

Mouse Response

• Host Strain: CBA
• Vaccination Protocol: BALB/c, CBA, and C57BL/6 mice were immunized intraperitoneally with M-2 at a final concentration of 0.03 mg/ml. The amount of C. parvum used in immunizations 2 and 3 was reduced to 0.05 mg per immunization (Champsi and McMahon-Pratt, 1988).
• Challenge Protocol: Animals were rested for 2 to 4 weeks after final immunization and challenged in the right hindfoot with late-log-phase promastigotes. Parasites used for infections were passaged a maximum of four times. Challenge doses of 10^3, 10^4, 10^5, and 10^6 were used (Champsi and McMahon-Pratt, 1988).
• Efficacy: Immunization of CBA mice with the M-2 glycoprotein of L. amazonensis and C. parvum adjuvant resulted in complete protection against a challenge infection of 10^4 and 10^6 late log-phase promastigotes of L. amazonensis. In the BALB/c strain, complete protection was observed in some of the immunized animals (28 to 50%); in the rest of the mice the onset of infection was significantly delayed. Protective immunity for C57BL/6 mice was observed only at the low infecting dose (10(4) L. amazonensis organisms) (Champsi and McMahon-Pratt, 1988).